P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site
Table 1
Clinical and pathologic features of primary breast tumors.
Primary tumors from patients who did not develop distant metastasis
Primary tumors from patients who developed distant metastasis
Luminal A
HER2
TN
Luminal A
Luminal B
HER2
TN
Histology
IDC
22 (96%)
9 (100%)
10 (100%)
20 (77%)
3 (60%)
4 (100%)
5 (100%)
ILC
0
0
0
5 (19%)
1 (20%)
0
0
Other
1 (4%)
0
0
1 (4%)
1 (20%)
0
0
Grade
Low
14 (61%)
0
0
2 (8%)
0
0
0
Intermediate
7 (30%)
1 (11%)
0
18 (70%)
3 (60%)
0
0
High
2 (9%)
8 (89%)
10 (100%)
6 (23%)
2 (40%)
4 (100%)
5 (100%)
LVI
Present
2 (9%)
1 (11%)
2 (20%)
13 (50%)
4 (80%)
3 (75%)
3 (60%)
Absent
21 (91%)
8 (89%)
8 (80%)
13 (50%)
1 (20%)
1 (25%)
2 (40%)
Lymph node involv.
Present
5 (22%)
0
0
(68%)
(100%)
(100%)
2 (40%)
Absent
18 (78%)
9 (100%)
10 (100%)
(32%)
0
0
3 (60%)
Tumor size
≤2 cm
22 (96%)
5 (56%)
4 (40%)
(24%)
2 (40%)
0
2 (40%)
2.1–5 cm
1 (4%)
3 (33%)
6 (60%)
(58%)
1 (20%)
2 (50%)
2 (40%)
>5 cm
0
1 (11%)
0
(20%)
2 (40%)
2 (50%)
1 (20%)
not available for all cases within subgroup. TN, triple-negative; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LVI, lymphovascular invasion; involv., involvement.
